An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165 (Prism301)

This study has been completed.
Information provided by (Responsible Party):
BioMarin Pharmaceutical Identifier:
First received: March 18, 2013
Last updated: November 25, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2015
  Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)